Background: Men with familial prostate cancer (PCA) and African American men are at risk for
BACKGROUND
Several genetic single nucleotide polymorphisms (SNPs) have been identified from genomewide association studies (GWAS) to be associated with PCA risk, (6) and several GWAS markers have been evaluated for association to early-onset PCA in substudies. (7) (8) (9) (10) A chromosomal region of great interest in PCA genetics research is 8q24. (8, (11) (12) (13) (14) One study found that carrying the minor allele of one polymorphism (rs6983561) at chromosomal locus 8q24 was associated with an increased risk for PCA in men < 50 years.(7) Another chromosomal region of interest for potentially harboring PCA susceptibility variants is 17q12. (15) One study found that the A-allele of a polymorphism (rs4430796) at 17q12 increased the risk for PCA in men < 50 years. (16) New genomic regions of interest for PCA risk have continued to be identified. Some of these regions are on chromosomes 3, 6, 7, 10, 11, 19, and X.(9) One polymorphism (rs266849) on chromosome 19 was found to be associated with an increased risk for PCA in men < 60 years.(9) Another study examining genetic variants at 10q11 and Xp11 found that polymorphism rs10993994 was associated with a 2-fold increased risk for PCA in men < 65 years. (10) A subset of men in families with potential hereditary PCA may be at increased risk for earlyonset disease, and one study found a common variant in BRCA1 (rs1799950) was overtransmitted to younger men (age <50 years) affected with PCA from hereditary and early-onset PCA families. (17) Other polymorphisms that reside in known genes have been characterized for association to early-onset PCA. (18, 19) One study found a polymorphism (rs2171492) in Carboxypeptidase 4 to be associated with risk for aggressive PCA in men < 66 years.(18) Therefore, while markers associated with early-onset PCA from various studies are promising for identifying risk for disease diagnosis at younger ages, further study of the clinical information gained from these and other genetic markers is needed to help guide patients and physicians in making individualized screening recommendations.
Here we evaluate the potential clinical information gained from six genetic markers associated with early-onset PCA among high-risk men undergoing PCA screening.(7-10, 17, 18) These markers were chosen for study in high-risk men (men with familial PCA and African American men) as subsets of these men undergoing screening have been diagnosed with PCA at ages < 55 years.(3, 4) Genetic markers of early-onset PCA may add clinical information beyond predicting early-onset disease among high-risk men useful in refining screening decisions. We performed this study in an ethnically-diverse longitudinal cohort of high-risk men enrolled in a PCA early detection program with significant African American participation. We took a broad approach to evaluating the clinical role of early-onset genetic markers in order to formulate hypotheses regarding the potential role of genetic markers in clinical PCA risk assessment. based on these biopsy criteria, no biopsy is performed and the participant is recommended to return to clinic in one year for repeat screening. Men diagnosed with PCA within 6 months after their first visit to PRAP were excluded (n=42) in order to eliminate pre-existing PCA from this analysis.
METHODS

Prostate Cancer Risk
Genotyping of six early-onset genetic polymorphisms. Six genetic markers reported to be associated with early-onset PCA were chosen for this study: rs6983561 (8q24), (7) rs4430796 (17q12), (8) rs266849 (19q13),(9) rs10993994 (10q11),(10) rs1799950 (17q21), (17) and rs2171492 (7q32). (18) Genotyping was performed on genomic DNA using a fluorogenic 5' nuclease allelic discrimination assay (TaqMan® SNP Genotyping Assay, Applied Biosystems). Reactions were prepared using TaqMan Universal PCR Mastermix, No AmpErase UNG or TaqMan Genotyping MasterMix (Applied Biosystems) according to manufacturer's instructions. Thermal cycling and analysis were performed using an ABI7900 Sequence Detection System (Applied Biosystems). Control DNA samples with known genotypes were included in each run. In addition, a no template (water) control was included to assess DNA contamination. SNP assignment was achieved automatically with the SDS software (Applied Biosystems) using a proprietary algorithm. In addition, genotypes were confirmed on a random selection of 2% of the samples by standard sequencing with 100% concordance.
Statistical Methods. Distribution of early-onset markers was summarized by self-reported race and compared using the chi-squared test. In addition, Hardy-Weinberg equilibrium was tested for each allele using the chi-squared test. (22) Time to PCA Diagnosis. For inferences on the relationship between time to PCA and the markers, individual genotype-specific Kaplan-Meier curves were constructed. Each SNP was examined as three genotypes, and then collapsed into the heterozygous or homozygous genotypes.
Time from enrollment to PCA was analyzed. Participants were censored at the last follow-up if they were not diagnosed with PCA at the time of the analysis. Cox proportional hazards regressions were used with each marker tested separately among African American and Caucasian men, and adjusted for age and PSA at baseline. Continuous variables were entered as linear terms in models. The risk genotypes were determined as those that created the most separation in the Kaplan-Meier curve, had larger hazard ratios, and greater level of statistical significance.
PSA Prediction for PCA by genotype.
To evaluate the effect of early-onset marker genotype on longitudinal prediction for PCA by PSA at baseline, the interaction terms between PSA at baseline and risk genotype were entered into each Cox model. To account for multiple hypotheses testing, we set the false discovery rate to 5% using Benjamini and Hochberg's method. PSA were entered into the Cox model as restricted cubic splines. The 3-year probabilities of being diagnosed with PCA were estimated for each participant. The estimated probabilities were plotted against the baseline PSA. Due to multiple age values, restricted cubic splines were fit to all estimated probabilities to represent the trend of the PSA prediction in each subpopulation.
Predictive accuracy of genetic markers. Harrell's C index was used to evaluate the accuracy of longitudinal prediction for PCA by early-onset markers and PSA. We created a training dataset and validation dataset by randomly assigning each observation to either dataset and used the program somerd in STATA to compare Harrell's C from different models.(24) Considering our outcome was longitudinal prediction for PCA and traditional area under the ROC curve analyses do not take into account the varied follow-up time, we used the C index which is a member of the "Kendall family" of rank parameters and is used to estimate the concordance probability with censored data. Like AUC, a value of 0.5 implies complete discordance. Higher values suggest higher concordance between the data and the predicted values from the model. All analyses were performed using STATA 10.1.
RESULTS
Genotype Distribution. At the time of this analysis, 778 participants were accrued to PRAP. Genotype distributions in the overall cohort for all six early-onset genetic markers differed significantly by race (Supplementary Table 1 ). Genotype distribution differences were also evaluated comparing those included in this analysis (n=460) and those excluded (n=310) for African American and Caucasian PRAP participants (Supplementary Table 2 
(n=13), missing clinical data (n= 4), diagnosed with PCA within 6 months of first PRAP visit (n=42) and no follow-up (either lost to follow-up after first visit or first visit was within 12 months of this analysis and participant was not due for follow-up) (n=251). Men diagnosed with PCA within 6 months were removed to exclude pre-existing PCA. The demographics of this sample set of 460 participants included in the analysis by self-reported race are shown in Table 1 . Approximately 56% of participants in the analysis were African American. The mean age at diagnosis for Caucasian participants was 57.5 years (range 46.3-67.4 years) and for African American participants was 57.5 years (range 40.8-73.7 years). The mean time to PCA diagnosis for African American men was 37.9 months (range 6.4-92.0 months) and for Caucasian men was 54.7 months (range 9.4-131.7 months).
Analysis of clinical role of genetic markers of early-onset PCA.
Out of the 460 participants included in this analysis, genotypes were able to be determined by marker as follows: rs6983561 (n=441), rs4430796 (n=430), rs266849 (n=436), rs10993994 (n=447), rs1799950 (n=444), and rs2171492 there was a trend toward AC genotype influencing PSA prediction for PCA (p=0.04) ( Table 3 ). The predicted probability of developing PCA at three years by rs6983561 genotype is represented in Figure   2 . None of the other five early-onset genetic markers influenced PSA prediction for PCA in this analysis.
Assessing predictive accuracy for PCA. Analysis of the predictive accuracy for PCA was performed only for rs6983561 as this marker was associated with earlier time to PCA diagnosis and with higher prediction for PCA by the baseline PSA. Table 4 , the magnitude of risk for PCA is typically modest with odds ratios less than 2.0.(6) Therefore, the clinical role of these markers and assessing individual risk for PCA is unclear. A particular subgroup of men to benefit from efforts to understand individual risk and clinical role of genetic markers are men with familial PCA and African American men as these men are susceptible to early-onset disease which has greater potential impact for PCA-related morbidity and mortality.
Our study was performed to evaluate genetic markers associated with early-onset PCA and gain an understanding of the potential clinical information these markers may provide that can be useful to the individual patient for risk assessment. We assessed the clinical information gained from six genetic markers previously associated with early-onset PCA and evaluated these markers for their prediction of time to PCA diagnosis, influence on PSA prediction for PCA, and accuracy of these 
markers over the PSA in predicting PCA in an ethnically-diverse, longitudinal cohort of high-risk men enrolled in PCA early detection. Out of the six early-onset markers analyzed, our results show that rs6983561 is informative in predicting time to PCA diagnosis among African American men. In addition, this marker influences PSA prediction for PCA and adds predictive accuracy to PSA for longitudinal prediction for PCA. Our findings suggest that markers associated with early-onset PCA deserve further clinical study as they may add useful clinical information that can help guide clinicians and patients in making PCA screening recommendations in order to diagnose life-ending PCA at a curable point and decrease unnecessary biopsies in high-risk men.
Our study found that rs6983561 genotype has potential clinical use in PCA risk assessment.
This polymorphism is located at chromosomal locus 8q24,(6) which is a gene-poor region. The actual function of rs6983561 is unknown; however the c-myc proto-oncogene is located downstream of this region. Studies to date have not found an effect on c-myc expression based on carrier status of markers at 8q24,(25) but research is ongoing to determine potential alternate mechanisms leading to PCA risk. (26) There are some limitations to consider when interpreting the findings of this study. It is noted that there may be clinical utility from the other markers in this study which were not detected due to our sample size. Our results need further confirmation and validation in larger sample sets. Our study did not identify PCA of higher Gleason score. Further research will need to be performed to determine if identifying intermediate risk PCA will have clinical impact with reducing morbidity and mortality from PCA, particularly in younger men. The overall follow-up rate in the PRAP cohort is 66.8%, which may have limited the ability to detect the clinical impact of the other early-onset genetic markers. However, we did not find any difference in genotype distribution between those included vs. excluded from the analysis except for rs4430796 which was not associated with significant findings in the clinical analysis. results. Confirmation of our findings is required in larger longitudinal screening studies. Finally, more genetic markers associated with early-onset PCA are being identified and will need study regarding their clinical role in PCA risk assessment. (27) Overall, our study finds early-onset genetic marker rs6983561 to provide potentially important clinical information regarding time to PCA diagnosis and influences PSA prediction for PCA among African American men. Validation of these findings regarding rs6983561 is needed prior to drawing definitive conclusions regarding the incorporation of this marker in PCA risk assessment. In an era where genomic information is becoming rapidly available due to advances in technology, it is imperative to study the clinical information gained from genomic markers in order to develop optimal early detection approaches. Efforts to elucidate the clinical utility of genetic markers associated with earlyonset PCA or clinically-meaningful PCA should inform future personalized risk assessment. 
